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Background: Neuromyelitis optica (NMO) is a serious inflammatory demyelinating disease (IDD), characterized by
the inflammation and demyelination of optic nerves and spinal cords, which subsequently leads to the loss of
function. In a previous genome-wide association study, cluster of differentiation 58 (CD58) region was found to be
susceptible for the risk of multiple sclerosis (MS) in Caucasian, and the association between CD58 variants and MS
was replicated in Americans. However, no study has been conducted to explore the possible association between
CD58 and NMO yet. Thus, this study aimed to investigate the association of CD58 polymorphisms with the risk of
NMO in a Korean population.
Methods: Using TaqMan assay, 6 single nucleotide polymorphisms (SNPs) were genotyped in 98 NMO patients and
237 normal controls (N = 336). Logistic regression analysis was conducted to find a possible association between
CD58 polymorphisms and NMO.
Results: The analysis results showed that 6 variations (rs2300747, rs1335532, rs12044852, rs1016140, CD58_ht1, and
CD58_ht3) showed significant associations (P = 0.002 ~ 0.008, Pcorr = 0.01 ~ 0.04).
Conclusion: The genetic variations in CD58 may be associated with the susceptibility of NMO in a Korean
population. Based on previous studies, we suspect that the A allele of rs2300747 may decrease CD58 RNA
expression, thus increasing NMO risk. Also, we deduced that the G allele of rs1016140 caused an increase of T cell
activity, which in turn eased the access of AQP4 antibody into central nervous system (CNS) and ultimately leading
to NMO development.
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Neuromyelitis optica (NMO), which belongs to inflamma-
tory demyelinating diseases (IDDs), is caused by the de-
myelination of axons in optic nerves and spinal cords.
Although NMO has similarities with multiple sclerosis
(MS), previous studies reported that MS and NMO may
have different etiology [1-3]. In MS, demyelination causes
symptoms such as a loss of sensitivity, hypoesthesia, par-
enthesis, disturbance of vision such as double vision, and
muscle weakness. On the other hand, a loss of vision and
spinal cord function are the most significant symptoms in* Correspondence: hdshin@sogang.ac.kr
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unless otherwise stated.NMO [1,2]. It is also known that the prevalence of MS is
higher in Caucasians than Asians (1 ~ 4/100,000 in Asian
vs. 30 ~ 150/100,000 in Caucasian) [4,5]. Contrary to MS,
the prevalence of NMO is higher in non-Caucasians in-
cluding African, Hispanic, and Asian [6].
Previous studies have shown that IDDs are complex-trait
diseases with both genetic and environmental factors.
However, compared to MS, there have been far less studies
on NMO. In our previous study, a genome-wide associ-
ation study (GWAS) was conducted for NMO and MS,
showing that the risk polymorphisms for NMO and MS
were different from each other [7]. Another study con-
ducted in our group has shown that SNPs in cluster of
differentiation 6 (CD6) and tumor necrosis factor receptor
superfamily member 1A (TNFRSF1A) were associated with
NMO, but not with MS [8]. These studies have shown that. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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studies of NMO independently.
Cluster of Differentiation 58 (CD58), also known as
lymphocyte function-associated antigen 3 (LFA-3), is one
of cell adhesion molecules abundantly expressed on anti-
gen presenting cells (APCs) [9]. Conjugation between
CD58 and CD2 or LFA-2, expressed in T-cell, is crucial
for T-cell activation [10]. Furthermore, the importance of
T-cell in MS development is well documented in previous
studies [11,12]. To date, several association studies were
conducted between CD58 and IDDs since the first GWAS
identified the gene’s association with MS [13]. Follow-up
studies have shown that CD58 SNPs such as rs2300747
and rs12044852 were associated with MS risk [14-18].
However, no study has looked into the association be-
tween CD58 and NMO. Therefore, in the present study,
we have conducted association studies between CD58
polymorphisms and NMO in a Korean population.Methods
Subjects
For genotyping of CD58 polymorphisms, 98 NMO pa-
tients and 237 controls were recruited. In order to study
biologically homogenous population, all the patients
showed both optic neuritis and longitudinally extensive
transverse myelitis following the revised diagnostic cri-
teria for NMO [19], and seropositive for aquaporin-4
antibody [20]. Anti-AQP4 antibodies were measured by
using an enzyme-linked immunosorbent assay (ELISA)
[21] and cell-based assay (CBA) with a commercial slide
kit (Euroimmun, Luebeck, Germany) [22]. In addition,
237 healthy controls of Korean ethnicity were included
(Age = 47.3 (38.0 - 60.0), Female/Male = 156/81) who did
not have characteristics of inflammatory demyelinating
diseases including NMO, classical MS, optic neuritis and
transverse myelitis. The study protocol was approved by
the Institutional Review Board of the National Cancer
Center of Korea. We obtained agreement of each subject
by written information before beginning the study. The
information of the subjects for present study is summa-
rized in Table 1. Detailed demographic and clinical char-
acteristics of NMO patients were previously described
elsewhere [23].Table 1 Characteristics of study subjects
NMO Control
Number of subject 98 237
Sex (M/F) 10/88 81/156
Age (mean (min.-max.)) 39.9 (11–67) 47.3 (38–60)
Onset age (mean ± Std) 33.5 ± 12.26 -
Duration (year, mean ± Std) 7.0 ± 4.42 -
NMO, neuromyelitis optica.Single nucleotide polymorphism (SNP) selection and
genotyping
Six SNPs of CD58 were selected based on following condi-
tions: (1) linkage disequilibrium (LD, minor allele fre-
quency (> 0.05)), (2) locations (SNPs in exons were
preferred), (3) previously reported SNP, (4) amino acid
changes (non-synonymous SNPs were preferred). Geno-
type data of Asian (Chinese and Japanese) population
from database of International HapMap Project (http://
hapmap.ncbi.nlm.nih.gov/) were used for selection. Then,
the selected SNPs were genotyped in 99 NMO cases and
237 healthy controls using TaqMan assay on the ABI
prism 7900HT sequence detection system (Applied Bio-
systems, USA). The TaqMan primer information was
listed in Additional file 1: Table S1.
Statistics
LD was obtained using the HaploView software (version
4.2) from the Broad Institute (http://www.broadinstitute.
org/mpg/haploview), with examination of Lewontin’s D’
(|D’|) and the LD coefficient r2 between all pairs of bi-
allelic loci [24]. P-values for Hardy-Weinberg equilibrium
(HWE) were also calculated using the HaploView soft-
ware. Haplotypes were first estimated using PHASE soft-
ware [25], and then computed using Statistical Analysis
System (SAS). Associations for NMO under logistic model
were adjusted by age (continuous value) and sex (male = 0,
female = 1) as covariates using SAS. In order to correct for
the multiple testing error, the SNPSpD program (http://
gump.qimr.edu.au/general/daleN/SNPSpD/) was used,
with the correction number of 4.5055. An in silico ana-
lysis was conducted by using Pupasuite 3.1 (http://
pupasuite.bioinfo.cipf.es/) [26].
Results
In the present study, we obtained the genotype informa-
tion of 336 subjects comprised of 98 NMO patients and
237 healthy subjects. Detailed clinical information about
the subjects is summarized in Table 1. A total of 6 SNPs
was genotyped for the study, and their location, haplo-
types, and LD map are displayed in Figure 1. For the
present study, only the haplotypes with frequencies over
0.05 were used. In addition, genotype frequencies, hetero-
zygosity, and P-values of HWE are shown in Additional
file 1: Table S2. All of the polymorphisms in the study
were in HWE except rs17426456, which was located in
the exonic region. The comparisons of CD58 SNPs fre-
quencies in Asian, Caucasian, and African populations
showed that there were distinct differences among them
(Additional file 1: Table S3). In order to compare the LD
structures among populations, we have also drawn LD
maps for African, Asian, and Caucasian in Additional file 1:
Figure S1 (A, B, and C respectively). The results showed
that the LD structure of Korean population was similar
Figure 1 Schematic physical map, haplotypes and LD status of CD58 polymorphisms. (A) Polymorphisms identified in CD58. Coding exons are
marked by shaded blocks and un-translated region (UTR) by white blocks. The LD coefficients (r2) are based on the genotypes of Korean samples.
(B) Haplotypes of CD58 in the Korean population. Only those with frequencies over 0.05 are shown. Others contain rare haplotypes: AATCGC, GGCATC,
AGCCTC, AGTCGT, GGCCGC, AGCCGT, AGCAGT, AATATC, AGCATT, AGTCGC, AGTATC, AACCGC, AATAGT, and AACATC. (C) LD coefficients (|D’| and r2)
among the selected SNPs based on the genotypes of whole study subjects in this study (n = 335).
Table 2 Association analysis using CD58 polymorphisms
and haplotypes with NMO risk
SNP/Haplotype MAF OR (95% CI) P Pcorr
Case Control
(n = 98) (n = 237)
rs17426456 0.046 0.051 0.92 (0.45-1.88) 0.79 NS
rs2300747 0.490 0.354 1.73 (1.23-2.43) 0.007 0.03
rs1335532 0.520 0.367 1.87 (1.33-2.63) 0.002 0.01
rs12044852 0.454 0.601 1.80 (1.28-2.53) 0.004 0.02
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casian. In contrast, the LD structure of African population
was clearly distinct from other populations.
In order to examine the possible association between
CD58 and NMO, we conducted association analysis
between CD58 polymorphisms and NMO (Table 2).
Statistical analyses revealed that 4 SNPs (rs2300747,
rs1335532, rs12044852, and rs1016140) and 2 haplo-
types (CD58_ht1 and CD58_ht3) showed significant as-
sociations with the risk of NMO (P = 0.002 ~ 0.008,
Pcorr = 0.01 ~ 0.04) (Table 2).rs1016140 0.535 0.395 1.76 (1.25-2.47) 0.005 0.02
rs12025416 0.412 0.312 1.55 (1.09-2.20) 0.06 NS
CD58_ht1 0.456 0.451 1.69 (1.22-2.34) 0.006 0.03
CD58_ht2 0.234 0.281 1.52 (1.06-2.17) 0.12 NS
CD58_ht3 0.089 0.063 2.13 (1.19-3.84) 0.008 0.04
Logistic regression analyses were performed for calculating odds ratio (95%
confidential interval) and P-values for SNP sites and haplotypes. Age
(continuous value) and sex (male = 0, female = 1) were adjusted by inclusion in
logistic analysis as covariates. To obtain the optimal correction for multiple
testing of single-nucleotide polymorphisms (SNPs) in linkage disequilibrium
(LD) with each other, the effective number of independent marker loci
(4.5055) in CD58 was calculated using the web based software SNPSpD
(Http://genepi.qimr.edu.au/general/daleN/SNPSpD), on the basis of the spectral
decomposition (SpD) of matrices of pairwise LD between SNPs. Significant
associations (<0.05) are italicized. MAF, minor allele frequency; Pcorr, corrected
P-value using multiple testing corrections; OR, odds ratio; CI, confidence
interval; NMO, neuromyelitis optica.Discussion
In the present study, we have conducted logistic analysis
to find a possible significant association between CD58
polymorphisms and NMO in a Korean population. Pre-
viously, several studies have reported the associations of
CD58 polymorphisms such as rs12044857, rs1335532
and rs2300747, with MS [13,17,18]. Our results showed
that the SNPs reported to be associated with MS
(rs2300747, rs13355332, and rs12044852) in previous
studies [15,17] were significantly associated with NMO
as well. In addition, rs1016140, which was not previously
studied for MS or NMO, also showed a significant asso-
ciation in our results.
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and NMO etiologies [27], the two diseases still share
similar symptoms and onset mechanisms, in which the
body’s immune systems are misdirected to attack its
own CNS. While CD58 polymorphisms had never been
studied in association with NMO, there were several
studies which reported significant associations of CD58
variants with MS. Therefore, in Table 3, we listed the re-
sults of such studies and compared them with the
present study result. The comparison showed that while
the diseases and ethnicities were different between the
previous MS studies and the present NMO study, the
polymorphisms rs2300747 (OR = 1.20 - 1.39 in previous
MS studies and 1.80 in the present study, P <0.05 in all
studies), rs1335532 (1.28 in a previous MS study with Cau-
casian populations and 1.87 in the present study, P < 0.05
in both studies), and rs12044852 (1.22 and 1.56 in previous
MS studies (P = 1.1 × 10−6 and 0.093 respectively) and 1.73
in the present study (P = 0.007)) were significantly associ-
ated with both MS and NMO in similar trends.
In order to further study the function of the CD58
SNPs, we have conducted in silico analysis of the 4 in-
tronic SNPs associated with NMO. As a result, no SNPs
were predicted to cause alternative splicing or be an
exonic splicing enhancer or silencer (data not shown).
However, previous reports suggest that there may be
functional backgrounds on at least 2 SNPs, rs2300747 and
rs1016140. In a recent study, the G allele of rs2300747
was found to limit the MS inflammation by increasing the
CD58 RNA expression [17]. In our study, we showed that
the A allele of rs2300747 was associated with the in-
creased risk for NMO (Pcor. = 0.03, OR (95% CI) = 1.73
(1.23-2.43)). We suspect that the decreased CD58 RNA
expression, caused by the A allele, may increase NMO risk
as well, although further functional studies are required to
confirm this notion.
A recent study has shown that T cell-mediated central
nervous system (CNS) inflammation is a pre-requisite forTable 3 Comparison of previous studies on CD58 – MS/NMO a
Reference Study populations Study su
(case/co
Hafler et al. (2007) [13] US and UK (MS) 2322/5418 (154
Rubio et al. (2008) [16] Australia (MS) 1134/
Bahlo et al. (2009) [18]* Australia, NZ, UK, and US (MS) 3874/
De Jager et al. (2009) [17]* US, UK, Belgium, Japanese,
Chinese, and Finland (MS)
3558/4420 (176
Brynedal et al. (2009) [28]* Swedish (MS) 1077/
Qiu et al. (2013) [29] Australia (MS) 350/
Present study Korean (NMO) 99/2
*Since these studies had reversed minor and major alleles compared to the presen
are values below 0.05, which indicate significance.the access of AQP4 antibody into CNS, an integral step in
the development of NMO [30]. In a separate study, it was
reported that rs1016140 was associated with the decreased
peak antibody level of hepatitis B virus and decreased
T cell activity [31]. Another study also reported that
the CD58 haplotype (rs1414275-rs11588376-rs1016140)
might affect the response level of CD58 with T cell co-
stimulatory molecules to decrease the T cell activity [32].
In the present study, the G allele of rs1016140 was associ-
ated with the increased NMO risk. We suspect that the in-
creased T cell activity caused by the G allele may lead to
the more robust CNS inflammation, which in turn eases
the access of AQP4 antibody into CNS, and ultimately
leads to NMO development. Further studies would be
needed to confirm our notion about the role of rs1016140
in the NMO etiology.
Although our study reports a potential association be-
tween CD58 polymorphisms and NMO, some limita-
tions are present which should be addressed in the
future. First, number of patients and controls enrolled in
the study was relatively small, due to the rarity of the
disease. This might have caused the low P-value of
HWE for rs17426456. Second, there was a disparity in
the gender ratio, as there were far more female subjects
than male subjects in the study. However, it has been re-
ported that NMO is approximately 3 to 5 times more
common in women than men [33]. In addition, associ-
ation analysis was adjusted for gender to accommodate
for this disparity. Lastly, functional study would be re-
quired to examine the actual effect of CD58 SNPs.
Conclusions
We have conducted association analyses between CD58
polymorphisms and NMO to find that 4 SNPs and 2
Haplotypes of CD58 were significantly associated with
the increased risk of NMO. From previous studies, we
have deduced the possible functional background of
rs2300747 and rs1016140, but the roles of otherssociation
bjects Study allele
ntrol) rs12044852 rs1335532 rs2300747
P-value (OR) P-value (OR) P-value (OR)
0 family trios) 1.9 × 10−5 (1.24) - -
1265 0.042 (1.20) - -
5723 - 9.6 × 10−8 (1.28) -
8 family trios) - - 1.1 × 10−6 (1.22)
1217 4.3 × 10−4 (1.39) - -
498 - - 0.093 (1.56)
37 0.004 (1.80) 0.002 (1.87) 0.007 (1.73)
t study, we modified their results to conform to our results. Italicized P-values
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http://www.biomedcentral.com/1471-2377/14/57polymorphisms remain unknown. Our study is the first
to find significant association between CD58 polymor-
phisms and NMO in a Korean population. However, fur-
ther studies may be required to confirm the functional
role of CD58 polymorphisms with NMO. We expect the
results in the present study to provide a new insight on
the role of CD58 in NMO and be helpful in developing
new treatments for the diseases.
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